From chronic kidney disease to transplantation: The roles of obestatin

Regulatory Peptides

Volumn 171, Issue 1-3, 2011, Pages 48-52

  Lacquaniti, Antonio ^a   Donato, Valentina ^a   Chirico, Valeria ^a   Pettinato, Giuseppina ^a   Buemi, Michele ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Chronic kidney disease; Kidney transplantation; Obestatin; Vascular calcification

Indexed keywords

CALCIUM; OBESTATIN; PARATHYROID HORMONE; PHOSPHORUS;

ADULT; ARTICLE; BODY MASS; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; ENERGY METABOLISM; FEMALE; GRAFT RECIPIENT; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE METABOLISM; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

ADULT; AGED; BODY MASS INDEX; CALCIUM; FEMALE; GHRELIN; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PHOSPHORUS; STATISTICS AS TOPIC;

EID: 80051805238     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2011.07.003     Document Type: Article

References (34)

1. Zhang J.V., Ren P.G., Avsian-Kretchmer O., Luo C.W., Rauch R., Klein C., et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005, 310:996-999.
2. Ariysu H., Takaya K., Tagami T., Ogawa Y., Hosoda K., Akamizu T., et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 2001, 86:4753-4758.
3. Wren A.M., Small C.J., Abbott C.R., Dhillo W.S., Seal L.J., Cohen M.A., et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes 2001, 50:2540-2547.
4. Kalantar-Zadeh K., Kopple J.D. Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. Am J Kidney Dis 2001, 38:1343-1350.
5. US Renal Data System USRDS 1997 Annual Data Report, National Institutes of Health, Bethesda, MD. National Institute of Diabetes and Digestive and Kidney Diseases 1997, 72-73.
6. Lacquaniti A., Bolignano D., Donato V., Bono C., Fazio M.R., Buemi M. Alterations of lipid metabolism in chronic nephropathies: mechanisms, diagnosis and treatment. Kidney Blood Press Res 2010, 33:100-110.
7. Teplan V., Valkovsky I., Teplan V., Stollova M., Vyhnanek F., Andel M. Nutritional consequences of renal transplantation. J Ren Nutr 2009, 19:95-100.
8. Lacquaniti A., Bolignano D., Donato V., Chirico V., Romeo A., Loddo S., et al. Obestatin: a new element for mineral metabolism and inflammation in patients on hemodialysis. Kidney Blood Press Res 2011, 34:104-110.
9. Jarkovská Z., Rosická M., Kršek M., Sulková S., Haluzík M., Justová V., et al. Plasma ghrelin levels in patients with end-stage renal disease. Physiol Res 2005, 54:403-408.
10. Yoshimoto A., Mori K., Sugawara A., Mukoyama M., Yahata K., Suganami T., et al. Plasma ghrelin and desacyl ghrelin concentrations in renal failure. J Am Soc Nephrol 2002, 13:2748-2752.
11. Rodriguez Ayala E., Pecoits-Filho R., Heimbürger O., Lindholm B., Nordfors L., Stenvinkel P. Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study. Nephrol Dial Transplant 2004, 19:421-426.
12. Haluzík M., Sulková S., Svobodová J., Bedárová V., Bodláková B., Marková M., et al. Serum leptin levels in diabetic patients on hemodialysis: the relationship to parameters of diabetes metabolic control. Endocr Res 2000, 26:303-317.
13. Pan W., Tu H., Kastin A.J. Differential BBB interactions of three ingestive peptides: obestatin, ghrelin, and adiponectin. Peptides 2006, 27:911-916.
14. Bresciani E., Rapetti D., Donà F., Bulgarelli I., Tamiazzo L., Locatelli V., et al. Obestatin inhibits feeding but does not modulate GH and corticosterone secretion in the rat. J Endocrinol Invest 2006, 29:16-18.
15. Zamrazilová H., Hainer V., Sedlácková D., Papezová H., Kunesová M., Bellisle F., et al. Plasma obestatin levels in normal weight, obese and anorectic women. Physiol Res 2008, 57:49-55.
16. Egido E.M., Hernández R., Silvestre RA Marco J. Effect of obestatin on insulin, glucagon and somatostatin secretion in the perfused rat pancreas. Regul Pept 2009, 152:61-66.
17. Huda M.S., Durham B.H., Wong S.P., Deepak D., Kerrigan D., McCulloch P., et al. Plasma obestatin levels are lower in obese and post-gastrectomy subjects, but do not change in response to a meal. Int J Obes 2008, 32:129-135.
18. Guo Z.F., Zheng X., Qin Y.W., Hu J.Q., Chen S.P., Zhang Z. Circulating preprandial ghrelin to obestatin ratio is increased in human obesity. J Clin Endocrinol Metab 2007, 92:1875-1880.
19. Mafra D., Guebre-Egziabher F., Cleaud C., Arkouche W., Mialon A., Drai J., et al. Obestatin and ghrelin interplay in hemodialysis patients. Nutrition 2010, 26:1100.
20. Nakahara T., Harada T., Yasuhara D., Shimada N., Amitani H., Sakoguchi T., et al. Plasma obestatin concentrations are negatively correlated with body mass index, insulin resistance index, and plasma leptin concentrations in obesity and anorexia nervosa. Biol Psychiatry 2008, 64:252-255.
21. Teplan V., Poledne R., Scuck O., Ritz E., Vitko Š. Hyperlipidemia and obesity after renal transplantation. Ann Transplant 2001, 6:21-23.
22. Marrero D., Hernandez D., Tamajón L.P., Rivero M., Lampreabe I., Checa M.D., et al. Pre-transplant weight but not weight gain is associated with new-onset diabetes after transplantation: a multi-centre cohort Spanish study. NDT Plus 2010, 3:15-20.
23. Abou-Jaoude M.M., Nawfal N., Najm R., Honeidi M., Shaheen J., Almawi W.Y. Effect of pretransplantation body mass index on allograft function and patient survival after renal transplantation. Transplant Proc 2010, 42:785-788.
24. Fung F., Sherrard D.J., Gillen D.L., Wong C., Kestenbaum B., Seliger S., et al. Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients. Am J Kidney Dis 2002, 40:307-314.
25. Qureshi A.R., Alvestrand A., Divino-Filho J.C., Gutierrez A., Heimbürger O., Lindholm B., et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 2002, 13:S28-S36.
26. Kalantar-Zadeh K., Kopple J.D. Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. Am J Kidney Dis 2001, 38:1343-1350.
27. Bonarek H., Merville P., Bonarek M., Moreau K., Morel D., Aparicio M., et al. Reduced parathyroid functional mass after successful kidney transplantation. Kidney Int 1999, 56:642-649.
28. Torres A., Rodriguez A.P., Concepcion M.T. Parathyroid function in long-term renal transplant patients. Nephrol Dial Transplant 1998, 13:94-97.
29. Sylvie Sulková Renální osteopatie. Hemodialỳza Maxdorf Praha 2000, 21:404-407.
30. Reinhardt W., Bartelworth H., Jockenhovel F., Schmidt-Gayk H. Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant 1998, 13:436-442.
31. Armando T., Lorenzo V., Salido E. Calcium metabolism and skeletal problems after transplantation. Am Soc Nephrol 2002, 13:551-558.
32. Hampl H., Steinmuller T., Frohling P., Naoum C., Leder K., Stabell U., et al. Long-term results of total PTX without autotransplantation in patients with and without renal failure. Miner Electrolyte Metab 1999, 25:161-170.
33. Li G.Z., Jiang W., Zhao J., Pan C.S., Cao J., Tang C.S., et al. Ghrelin blunted vascular calcification in vivo and in vitro in rats. Regul Pept 2005, 129:167-176.
34. Volante M., Rosas R., Ceppi P., Rapa I., Cassoni P., Wiedenmann B., et al. Obestatin in human neuroendocrine tissues and tumours: expression and effect on tumour growth. J Pathol 2009, 218:458-466.